| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
L-692,585 manufacturers
- L-692585
-
-
2026-05-11
- CAS:145455-35-2
- Purity:
- Supply Ability: 10g
|
| | L-692,585 Basic information |
| Product Name: | L-692,585 | | Synonyms: | L-692,585;L-692;3-[[(2R)-2-Hydroxypropyl]amino]-3-methyl-N-[(3R)-2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3-yl]-butanamide;3-[[(2R)-2-hydroxypropyl]amino]-3-methyl-N-[(3R)-2-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4,5-dihydro-3H-1-benzazepin-3-yl]butanamide;Butanamide, 3-[[(2R)-2-hydroxypropyl]amino]-3-methyl-N-[(3R)-2,3,4,5-tetrahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-1-benzazepin-3-yl]-;585;L 692585,L692585;Polypeptide Impurity 90 | | CAS: | 145455-35-2 | | MF: | C32H37N7O3 | | MW: | 567.68 | | EINECS: | | | Product Categories: | | | Mol File: | 145455-35-2.mol |  |
| | L-692,585 Chemical Properties |
| storage temp. | Desiccate at -20°C | | solubility | Soluble to 100 mM in DMSO and to 25 mM in ethanol | | form | Powder | | color | White to off-white |
| | L-692,585 Usage And Synthesis |
| Uses | L-692,585 shows potent and selective GH-secretory activity in several species including human. | | Definition | ChEBI: 3-[[(2R)-2-hydroxypropyl]amino]-3-methyl-N-[(3R)-2-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4,5-dihydro-3H-1-benzazepin-3-yl]butanamide is a peptide. | | Biological Activity | Highly potent, non-peptide ghrelin receptor (GHS-R1a) agonist (K i = 0.8 nM). Increases plasma GH levels in vivo and is 2- to 2.5-fold more potent than GHRP-6. | | in vivo | L-692585 (0.01-0.1 mg/kg; i.v. once daily for 2 weeks) increases peak plasma GH levels and total GH release[3].
L-692585 (0.005-0.1 mg/kg; a single i.v.) significantly increases peak GH concentrations 4.3-fold at a dose of 0.005 mg/kg, 7-fold at a dose of 0.02 mg/kg, and 21-fold at a dose of 0.10 mg/kg in vivo[3]. | Animal Model: | Beagles (1-1.5 years old ; weighting 8.5-16.0 kg)[3] | | Dosage: | 0.01, 0.1 mg/kg | | Administration: | I.v. once daily for 2 weeks | | Result: | Increased the peak plasma GH levels and total GH release on days 1, 8 and 15 in a dose-dependent manner, and no desensitization was evident. |
| | storage | Desiccate at -20°C |
| | L-692,585 Preparation Products And Raw materials |
|